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Abstract
Aging is a condition in which a person gradually loses the ability to maintain  homeostasis, 
due to structural alteration or dysfunction. Aging changes biological processes in many 
organs and tissues. The loss of regenerative capacity is the most dramatic age-associated 
alteration in the liver. Cellular damage, if not repaired, leads to apoptosis or senescence. 
The presence of permanent cell cycle arrest, the acquisition of major morphological 
change, and expression of senescence-associated β-galactosidase (SA-β-gal) are the 
 characteristics of cellular senescence (CS). Interestingly, CS plays a crucial role in aging 
of both individual organs and the entire organism; consequently, senescent cells accumu-
late in organs and decline in organ function. Senescent cells have considerable influence 
on their microenvironment and exert both beneficial and detrimental effects through 
secretory associated senescent phenotype (SASP) factors. CS has attracted considerable 
recent interest with recognition of pathways linking aging, malignancy, and insulin resis-
tance and the current focus on therapeutic interventions to extend healthspan. There are 
major implications for hepatology in the field of fibrosis and cancer, where cellular senes-
cence of hepatocytes, cholangiocytes, stellate cells, and immune cells has been implicated 
in chronic liver disease progression.
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1. Introduction
Aging is a biological process that consists of a series of structural and functional changes that 
appear over time and are not a consequence of diseases or accidents. In general,  tissues are 
comprised of specific cells that determine the tissue microenvironment. Various factors affect 
the cellular environment, such as oxygen pressure, oxidative stress, temperature, and  several 
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growth factors secreted by cells. Sometimes the cell’s microenvironment alters the tissue 
homeostasis, causing a permissive environment that favors tumor promotion and develop-
ment. This progressive aging is caused by multiple factors. The following nine characteristics 
are generally considered to contribute to the aging process: altered intracellular communication, 
genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated 
nutrient sensing, mitochondrial dysfunction, stem cells exhaustion, and cellular senescence [1].
2. Cellular senescence
Cellular senescence (CS) is a stable form of cell cycle arrest that limits the proliferative  potential of 
cells [2]. Senescence is the result of various degenerative changes characterized by shortening of 
the telomeres, chromosomic instability, DNA damage, oxidative stress  producing reactive oxygen 
species (ROS), and oncogene overexpression [3–10]. Some researchers consider CS the natural 
solution to prevent cell damage, which may lead to various diseases including cancer. In contrast, 
with age, CS is considered to promote several chronic diseases. The pathological effects of CS may 
affect the health of elderly people due to the accumulation of senescent cells in several organs and 
tissues because CS can impair tissue regeneration. Furthermore, senescent cells can release several 
molecules, such as growth factors, cytokines, and chemokines that alter cellular homeostasis [11].
Up to date, two basic mechanisms have been identified to induce senescence: replicative 
senescence and premature senescence. Replicative senescence, or the Hayflick limit, is associ-
ated with telomere attrition; telomere exhaustion causes the limited proliferative capacity of 
certain types of in vitro cultured cells [12]. Cells react to the loss of telomeres as if it is DNA 
damage, which therefore triggers the DNA damage response (DDR); the cellular response is 
similar to that initiated by external agents, for example, ionizing radiation and drugs.
In contrast, premature senescence is related to chromosomic instability, DNA damage, oxida-
tive stress, oncogene overexpression, and epigenetic changes. Senescent cells have a typical 
morphology in culture: cells are enlarged, vacuolated, and flattened and in some cases, they 
are multinucleated. However, in vivo senescent cells retain the normal morphology according 
to the tissue to which they belong. It has been found that these cells are metabolically active, 
and they can secrete growth factors, chemokines, and metalloproteases; this is known as the 
senescence associated secretor phenotype (SASP) [13].
2.1. Senescence markers
Senescent cells have several typical characteristics. First, they are positive for β-galactosidase 
activity at a suboptimal pH (pH 6), and this activity is based on the increment of lysosomal activ-
ity. One limitation of the β-gal assay is the need to use fresh or frozen samples [14]. Another 
characteristic is that senescent cells are in cellular arrest. Cellular arrest is an essential condition for 
 senescence to occur, as senescent cells are positive for Ki67 protein or  negative for the incorporation 
of  5-bromodeoxyuridine (Brdu) [15]. Other senescent markers are related to tumor  suppressors 
such as p53, p16, p21, and the hypophosphorylated Rb protein. Heterochromatin bodies are 
known as heterochromatin foci in the nucleolus. In cells with DNA damage, it is common to find 
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γ-H2AX histone phosphorylation which carries the DDR. Another finding is the decrease in lamin 
B1 levels as a common feature in many types of senescence [16, 17]. On the other hand, senescent 
cells have been found in biological processes other than aging as in systems such as humans, mice, 
and chicken embryos, suggesting that these cells are important to embryogenesis [18].
2.2. Senescence pathways
In the senescence process, there are two key tumor suppressors, the INK4/ARF locus and p53. 
The INK4/ARF locus allows the expression of three important proteins, p16Ink4a, p14Arf (p19Arf in 
mice), and p15Ink4b. Serrano et al. discovered the protein p16Ink4a. The p16Ink4a binds to CDK4/6 
cyclins, preventing the phosphorylation of the Rb protein family; therefore, the cell cycle is 
inhibited at the G1 phase and cells enter in a cellular arrest, and this pathway is known as 
p16Ink4a-Rb [19]. In contrast, p53 is a transcription factor, which transcribes target genes to regu-
late various biological cell processes in response to stress stimuli; the biological cell processes 
include apoptosis, senescence, energy metabolism, and antioxidant defense. p53 is stabilized 
and phosphorylated by upstream kinases including ataxia telangiectasia (ATM) and Chk2 [10, 
20, 21]. Phosphorylated p53 upregulates the transcription of its target gene, p21, which activates 
the Rb protein through the inhibition of cyclin E/Cdk2. The  hypophosphorylated Rb protein 
inhibits the transcription of E2F genes, including cyclin A and proliferating cell nuclear antigen 
(PCNA), which are required for cell cycle progression [22]. On the other hand, p14Arf is directly 
related to p53 and is linked to the mourin double murine 2 (Mdm2) protein; therefore, p53 is 
stabilized, and p21 is expressed and inhibits cyclin E/Cdk2 [23]. This senescent pathway is 
called the p53-p21 pathway. Another senescence-signaling pathway is through the p38 protein, 
which is a mitogen activated protein kinase (MAPK) protein that transforms a variety of stress 
stimuli into a common senescence signal [24]. The  inactivation of p38 delays the onset of vari-
ous forms of cellular senescence including replicative,  oxidative-stress-induced, and oncogene 
induced senescence. In contrast, enforced activation of p38 by a constitutive active form MAPK 
kinase (MKK6EE) of upstream kinase, MKK6, acutely induces cellular senescence [25, 26].
In recent years, other elements have been incorporated into the senescence pathway  regulation. 
Studies on genetic regulation in human fibroblasts and mice embryonic fibroblasts (MEFs) 
showed the presence of long noncoding RNAs (lncRNAs), which are derived from noncoding 
RNAs (ncRNAs). Tumor suppressors have specific lncRNAs; for example, several IncRNAs, 
such as focally amplified lncRNA on chromosome 1 (FAL 1), BRAF-activated non-protein 
coding RNA (BANCR), and long intervening noncoding RNAs (LINCRNA) p21, have been 
found in p21 [27–30]. In the case of p53, lncRNA metastasis associated lung adenocarcinoma 
transcript 1 (MALAT1) as well as 7SL have been related to p53 expression [31, 32]. The INK4a-
ARF locus and p16INK4amRNA are linked with lncRNAs VAD, antisense non-coding RNA 
in the INK4 locus (ANRIL), MIR31 host gene (MIR31), and Urothelial cancer associated 1 
(UCA 1) [33–38]. Another lncRNA associated with senescence is senescence-associated long 
non-coding RNA (SALNR), which is related to NF-9 [39]. telomeric repeat containing RNA 
(TERRA) is a lncRNA associated with telomere length [40]. Researchers have shown that 
lncRNAs are tightly regulated and  tissue specific. Moreover, the dysregulation of lncRNAs 
has been associated with human diseases. Further studies must be performed to accurately 
determine the functional role of these lncRNAs in senescence and aging [41].
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2.3. Chromatin alterations
Alterations in the structure of chromatin are believed to contribute to the irreversible nature of the 
senescent state. Narita et al. found that in DNA cells stained with  4’,6-diamidino-2-phenylindole 
(DAPI), chromatin bodies called foci can be observed at the nucleus [42]. It is likely that DAPI-
stained foci correspond to highly compacted  heterochromatin, as senescent cell chromatin is 
resistant to micrococcal nuclease digestion; moreover, DAPI foci contain numerous proteins 
characteristic of transcriptionally inactive heterochromatin, including hypoacetylated his-
tones, methylated histone H3 on Lys 9 (H3K9 me), and heterochromatin protein 1 (HP1). The 
formation of heterochromatin structures known as heterochromatin foci is associated with 
senescence-associated heterochromatin foci (SAHF). Various forms of stress induce SAHF for-
mation as well as other senescence phenotypes, suggesting that SAHFs can be used to identify 
senescent cells in vivo and that SAHF formation somehow contributes to the mechanisms of 
cellular senescence; although, not all senescent cells exhibit SAHFs [43].
2.4. Oxidative stress and liver senescence
Under normal physiological conditions, cells are protected from oxidative stress by an 
array of endogenous antioxidants that maintain a balance between pro-oxidant produc-
tion and  antioxidant capacity. An imbalance occurs when intracellular antioxidants are 
unable to  neutralize the pro-oxidants such as ROS, which are a number of highly reactive 
molecules derived from molecular oxygen [44]. ROS are mainly produced by the mito-
chondrial  respiratory chain, cytochrome P450, and autooxidation of endogenous sub-
strates such as heme proteins, catecholamines, quinones, among others [45]. ROS exert 
a broad array of biological effects, ranging from physiological regulatory functions to 
several oxidative modifications, which can contribute to the pathogenesis of various dis-
eases. ROS can also impact the cell by altering physiological and biochemical processes 
such as gene expression, cell adhesion, cell metabolism, cell cycle, cell disease, and cell 
death [46, 47]. Thus, oxidative stress has been confirmed to be a common participant 
in several diseases including liver diseases [48]. It has been proposed that the damage 
induced by oxidative stress may represent a common link between different chronic liver 
diseases. This proposal is supported by the fact that free radicals are key players not only 
in normal liver function but also in the genesis and progression of liver steatosis, fibrosis, 
cirrhosis, and hepatocellular carcinoma (HCC) [49, 50]. Therefore, a strong association 
is expected between oxidative stress and the pathogenesis of liver diseases. Oxidative 
stress is an inherent component in the liver as the activity of many enzymes involved in 
lipogenesis, fatty acid oxidation, cholesterol, and phospholipid metabolism is regulated 
by the redox status of liver parenchyma, which can influence the redox balance of the cell 
microenvironment [51]. Thus, following liver injury by different etiological factors [52], 
endogenously produced ROS may have an accumulative impact (mainly evidenced as an 
increase in lipid peroxidation), which plays a critical role in the progression of chronic 
liver diseases [53].
Several studies have proposed that ROS production is one of the main activators and 
 stabilizers of CS. Although this is a preliminary proposal, there is evidence demonstrating 
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a direct contribution of ROS to both the DDR and the redox-activated pathways [54, 55] and 
induces telomere shortening [56], which results in a DDR and senescence activation. Up to 
date, both experimental and clinical studies have strongly supported the association of CS 
with chronic liver diseases. In addition to specific parenchymal or nonparenchymal liver 
structures, studies have highlighted the appearance of CS in two paradoxical settings, as a 
tumor suppressor and as a tumor promoter, and in two physiological processes, aging and 
tissue repair [57, 58]. Cellular senescence is involved in multiple physiological processes; the 
complexity of CS may be elucidated by deciphering the mechanisms that induce its activation, 
such as oxidative stress. In this regard, evidence has shown that increased ROS production by 
mitochondrial dysfunction is triggered after a DDR and subsequent CS activation, which in 
turn is a consequence of p21 activation. The sequence of events maintains a dynamic feedback 
loop that is necessary for the stability of growth arrest during the establishment of the senes-
cent phenotype [59]. A similar phenomenon was observed during the activation of the p16/RB 
pathway, which induces high intracellular levels of ROS and thereby activates protein kinase 
C-Δ (PKC∆); consequently, further ROS are generated to establish a positive feedback loop 
to sustain ROS-PKC∆ signaling [60]. Other studies have reported that activation of the RAS, 
p21, and p53 pathways are also closely related to elevated ROS production [61, 62]. In these 
reports, N-acetylcysteine treatment blocked cell cycle arrest and thereby CS, demonstrating 
that ROS accumulation is an important mediator of CS; furthermore, researchers proposed 
that ROS are a causal agent of CS. The evidence confirms that ROS play a key role in the CS 
process; however, it is still unclear whether ROS are a consequence or cause of CS.
2.5. Reactive oxygen species and hepatic diseases
A variety of free radicals are found in the liver and can be classified as mitochondrial, prin-
cipally from complexes I and III, and extra mitochondrial, such as cytochrome P450,  xanthine 
oxidase, nitric oxide synthase, and nicotinamide adenine dinucleotide phosphate reduced 
(NADPH) oxidase. Where neutrophils and Kupffer cells primarily produce free radicals, the 
cytochrome P450 system and mitochondria are the major sites of ROS release in hepatocytes. 
An important mechanistic source of ROS is lipid metabolism, which is  dependent on the redox 
balance of the liver, and its alteration is closely linked to both alcoholic and nonalcoholic ste-
atohepatitis [51, 63]. The above-mentioned sources of ROS are strictly controlled in normal 
hepatocytes; however, in hepatic diseases, an overproduction of free  radicals can overcome the 
antioxidant defenses and induce liver injury [51]. Consequently, the liver is a continuous target 
of oxidative stress and redox balance. It is not surprising that an increasing number of findings 
have shown a close association between liver diseases and ROS production [63]. Clinical and 
experimental reports have suggested that CS onset may be an intrinsic phenomenon from the 
beginning of liver injury, such as the appearance of neoplastic nodules [64, 65]. This proposal is 
supported by the  presence of replicative and premature senescence in both parenchymal and 
nonparenchymal liver cells [58, 66, 67]. Using a liver injury model to mimic sequential HCC pro-
gression (from  fibrosis to cirrhosis and HCC) [68], we recently confirmed that CS appearance is 
intrinsic to the  initiation of liver injury, as a chronological increase of CS alongside HCC progres-
sion was observed [69]. We did not determine ROS levels in this investigation; however, HCC 
was induced with continuous diethylnitrosamine administration, a hepatotoxic and potent 
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ROS producer [70], suggesting that the chronological appearance of CS was accompanied by 
persistent ROS induction. In a recent study, the role of hepatocyte senescence in the devel-
opment of insulin resistance was investigated [71]. Using HepG2 cells, they demonstrated 
that H
2
O
2
 treatment induced CS despite insulin stimulation. This phenomenon was accom-
panied by a persistent nuclear localization of FoxO1, a transcription factor that, among oth-
ers, promotes the expression of genes involved in cell cycle arrest and detoxification of ROS. 
Moreover, an increase and decrease in the expression of glucose transporters 2 and 4 (GLUT2 
and GLUT4), respectively, were proposed as senescence markers, as this pattern was found 
in senescent HepG2, in human cirrhotic liver tissue, and in publicly available liver disease 
datasets. In a different study by the same research group, gene expression profiles of HepG2 
cells subjected to oxidative stress were compared with public microarray datasets obtained 
from human cirrhotic samples. The results showed that the gene upregulation profile of senes-
cent HepG2 cells induced by H
2
O
2
 treatment was similar to that in human cirrhotic livers. 
Interestingly, gene expression profile patterns of senescent hepatocytes were markedly linked 
to alterations in cell cycle regulation, morphology, metabolism, and stellate cell activation, 
which occur alongside impaired synthetic function in senescence [72]. Although these results 
suggest a close relationship between hepatocyte senescence and ROS action, the use of an 
external stressor agent to induce CS may be a key factor to work in an asynchronous man-
ner in the sequence of molecular events involved in intrinsic ROS production. More direct 
evidence has demonstrated a strong interconnection between senescence, ROS, and TGF-β 
signaling in chronic liver diseases. Borkham-Kamphorst et al. showed that the overexpression 
of cysteine-rich protein 61 (CCN1/CYR61) significantly inhibited the production of collagen 
type I and induced ROS, leading to CS and apoptosis in vivo and in vitro. This effect was 
associated with an attenuation of TGF-β signaling; as a result, CCN1/CYR61 overexpression 
mitigated liver fibrogenesis in a bile duct ligation model. This analysis is a clear example of 
ROS and CS induction as a potential molecular mechanism for tissue repair and remodel-
ing promoted by the manipulation of CCN1/CYR61 during hepatic injury [73]. In a similar 
study with contrasting reports, dioscin, a saponin plant steroid, promoted CS but decreased 
the oxidative stress induced by CCl4 in activated hepatic stellated cells (HSC). Among oth-
ers, this antifibrotic effect was associated with the attenuation of TGF-β/Smad, Wnt/β-catenin, 
MAPK, and mitochondrial signaling pathways [74]. Recent investigations have shown that 
Sir2 enzyme members, collectively called sirtuins, are involved in CS associated with liver 
diseases. Sirtuin 6 (SIRT6), an enzyme that promotes resistance to DNA damage and oxidative 
stress, plays a central role in the CS induced by ROS and TGF-β signaling in HCC cells [75]. 
In this report, ROS and TGF-β upregulated SIRT6 expression by inducing sustained activa-
tion of extracelular signal-regulated kinase (ERK) and Smad pathways. Upregulated SIRT6 
not only abrogated the inducing effect of TGF-β and ROS on CS but was also required for 
the ERK pathway to suppress p16 and p21 expression. Additionally, upregulation of SIRT6 
promoted HCC cell tumorigenicity and contributed to the inhibitory effect of the ERK path-
way on cellular senescence. This feedback loop activation integrated by SIRT6 and TGF-β 
has the potential to modulate both tumorigenicity and senescence and represents a clear 
example of the molecular complexity around senescence activation. Another investigation 
group demonstrated that SIRT1, an enzyme that deacetylates nonhistone proteins and allows 
mammalian cell survival under oxidative stress, is downregulated in aged and middle-aged 
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mice. This condition increased mice  susceptibility to the effect produced by chronic alcohol 
consumption and exacerbated alcoholic liver injury and fibrosis in hepatocytes and hepatic 
stellate cells [76]. This evidence clearly reveals that the senescence and ROS pair in the liver 
of elderly patients boosts alcohol liver disease, likely by the modification of liver metabolic 
functions. This proposal is in accordance with a recent report of Cyp2e1 as a central player in 
aging-dependent hepatic steatosis, apoptosis, and fibrosis. The investigation demonstrated 
that Cyp2e1 increased the production of reactive nitrogen species and ROS in aged mice; as 
a result, high levels of lipid peroxidation, oxidative protein modifications, oxidative DNA 
damage, and inflammation were found. These changes were absent or decreased in aged 
Cyp2e1-null mice [77]. In the serum of patients with nonalcoholic steatohepatitis (NASH) and 
NASH-related HCC, oxidative stress correlated with the levels of NASH activity markers, 
while the antioxidative function was preserved in younger patients as well as in patients with 
a well-preserved liver function; in contrast, patients with  NASH-related HCC tended to be 
older and exhibited a diminished antioxidative function [78]. In addition to the complexities 
involved with senescence and ROS in liver diseases, there is evidence of SIRT1 and Cyp2e1 as 
possible targets for preventing aging-related liver disease.
Senescence induction has also been another means for researchers to determine the efficiency of 
chemotherapeutic agents against cancer. Most of these agents are strong oxidative stress induc-
ers such as cisplatin. In a recent study, this compound promoted a senescent phenotype in HCC 
cell lines dependent on p53 and p21 activation and intracellular ROS generation [79]. Although 
senescence activation appears to be a natural consequence of oxidative stress induction, ROS 
generation may dictate different cellular consequences depending on the overall concentration 
at steady-state levels and site of generation [80]. In support of this, an advanced investigation 
has conferred an important role for ROS production and its participation as a decisive factor 
in the progression and aggressiveness of cancer [81], and has also raised the complexity of the 
senescence and ROS pair. Investigators reported that the normally high potential for mela-
noma cells to form subcutaneous tumors is limited after intravenous or intrasplenic transplan-
tation; this occurs because metastatic cells experience a charge of oxidative stress in the blood 
and visceral organs, which is not present in established subcutaneous tumors. To overcome 
that barrier, cells undergo reversible metabolic changes during metastasis that increase their 
capability to withstand oxidative stress. It was found that mitochondrial membrane potential, 
mass, and ROS levels declined more in circulating metastatic cells compared to subcutaneous 
tumors, raising the possibility that mitochondrial function is reduced in circulating melanoma 
cells in an effort to reduce ROS generation [81]. During the normal aging process, mitochon-
drial metabolic changes are implicated in the induction and maintenance of CS [82]. While the 
investigation did not show whether oxidative stress also limits the initiation and early growth 
of primary cutaneous cancer cells [81], it is reasonable to hypothesize that senescence activation 
and/or ROS generation are determinant factors of the appearance and progression of different 
multifocal HCC types. This intriguing hypothesis stems from a proposal that multifocal HCCs 
are either from an HCC of multicentric origin or HCC of intrahepatic metastasis [83]. Thus, 
in this scenario, ROS may modulate CS activation in the HCC microenvironment. As a result, 
senescence and ROS may be the decisive molecular pair to establish the outcome of multifo-
cal HCC. This hypothetical proposal also raises the question of whether the appearance of 
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 senescence/ROS is a transitory, sporadic, or specific event of a determined HCC development 
stage. We have recently shown that, concomitant to the HCC development induced by diethyl-
nitrosamine, there is also a chronological appearance of CS [69]; however, its association with 
ROS generation and effect on the outcome of multifocal HCC type has not been investigated. 
This is an interesting and comprehensive proposal worth investigating.
3. Is cellular senescence important in the development of 
hepatic diseases?
Aging changes the biological processes in many organs and tissues of mammalians, leading 
to the development of age-associated diseases and aberrant body homeostasis. Nearly 13% 
of the population in the United States is over the age of 65 years; this percentage and the 
number of elderly people will increase substantially over the next 50 years [84]. Although 
the aging process does not cause death, elderly people appear to be predisposed to a variety 
of diseases; therefore, aging facilitates the onset and/or progression of various pathologies 
including  diseases of the liver [84]. The ability to withstand hepatic insult decreases each 
decade, including those associated with high triglyceride levels, nonalcoholic fatty liver dis-
eases, and HCC [85–87]. The percentage of deaths caused by liver diseases increases dra-
matically in humans over the age of 45 years. Accordingly, age is a critical determinant in 
the outcome of hepatitis C infection [88] and liver transplantation [89]. However, the most 
dramatic effect of aging on the liver is its delayed and/or reduced proliferation after a loss 
of mass from a surgical or chemical injury [90–92]. Based on these correlations, it has been 
suggested that elderly people are predisposed to liver diseases. The livers of young individu-
als regenerate after these treatments and maintain homeostasis; conversely, there is a dra-
matically reduced regeneration of the livers of older people. The clinical outcome of human 
acute liver injury is also partially dependent on the potential for hepatic regeneration. In 
older people, there is a higher incidence of acute liver failure and a higher mortality with 
acute hepatitis A [93, 94]. In a cohort of patients with acute liver failure secondary to viral 
hepatitis, age was an independent predictor of a poor outcome, with the worst outcomes in 
people over the age of 50 years [95]. Wong et al. and Poynard et al. were among the first to 
demonstrate that age at infection was a major risk factor for subsequent fibrosis progression 
and that the rate of fibrosis progression accelerated with increasing age [96, 97]. Studies of 
other liver diseases have demonstrated similar findings. Age is an independent risk factor 
for poor outcomes in primary biliary cirrhosis (PBC) in addition to the presence of portal 
hypertension and impaired liver function [98]. Similarly, age, independent of bilirubin, pro-
thrombin time, and renal function, predicted the outcome in patients with alcoholic hepatitis 
[99]. There is some evidence that age may influence disease progression in nonalcoholic fatty 
liver disease (NAFLD) [100, 101].
The role of CS in diverse chronic liver diseases has come into recent research. The structure 
of hepatocytes changes with age. The volume of hepatocytes increases with development and 
maturation but declines with senescence [84]. The relative volumes of hepatocyte organelles 
also change during aging. The universal change in diagnostic liver biopsy specimens is the 
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age-related cytoplasmic accumulation of highly oxidized insoluble protein lipofuscin or age 
pigment, which in turn reflects a concomitant increase in the volume of the dense body com-
partment [102]. Accelerated hepatocyte aging and the accumulation of senescent hepatocytes 
have been found in diverse chronic liver disorders [103–108]. Furthermore, the studies have 
shown that the increased proportion of senescent hepatocytes is associated independently 
with increased fibrosis stage, impaired hepatic function, and an adverse liver-related out-
come including liver-related death [103–109]. However, it is still unknown whether hepato-
cyte senescence contributes causally to fibrosis progression, declining hepatic function, or the 
increased risk of an adverse liver-related outcome.
3.1. Hepatic fibrosis
Hepatic fibrosis is a common pathological consequence of chronic liver diseases and results 
from the progressive accumulation of an excess quantity of extracellular matrix (ECM) tis-
sue. In many patients, continuous liver parenchyma insult ultimately leads to cirrhosis [110]. 
The ECM accumulation during chronic liver injury is caused by a heterogeneous population 
of myofibroblasts derived mainly from hepatic stellate cells and from resident fibroblasts. 
Myofibroblasts are highly proliferative cells with enhanced survival that migrate and accu-
mulate at sites of liver damage in response to a liver insult that caused a wide variety of 
growth factors, cytokines, and lipid mediators. Recently, many studies have observed that the 
presence of an increased proportion of senescent hepatocytes is associated with an increased 
fibrosis stage. This results in impaired hepatic function and an adverse liver-related outcome, 
including liver-related death [103, 104, 106–108].
3.2. Cirrhosis and HCC
In humans, cirrhosis is induced by a variety of liver diseases. Regardless of its etiology, cir-
rhosis evolves slowly over many years, and chronic hepatocyte death and renewal are major 
predisposing factors [111]. Cirrhosis is associated with life-threatening complications due to 
a decreased functional parenchymal reserve and altered hepatic blood flow. A recent report 
by WHO indicates that cirrhosis accounts for 170,000 deaths in Europe per year [110]. The 
cellular growth arrest and CS appear to be in a pro-fibrotic state. There is existing research 
on the relation between cirrhosis and telomere shortening, showing that telomere shorten-
ing is a marker of cirrhosis and correlates with senescence-associated β-galactosidase in 
84% of cirrhosis samples, specifically in hepatocytes [110]. CS contributes to age-related 
tissue dysfunction, macroH2A1, and a variant of histone H2A. CS is also a marker of senes-
cence-associated heterochromatic foci that synergizes with DNA methylation to silence 
tumor-suppressor genes in human fibroblasts. MacroH2A1, a variant of histone H2A, is a 
marker of senescence-associated heterochromatic foci that synergizes with DNA methyla-
tion to silence tumor-suppressor genes in human fibroblasts. In a recent study, Borghesan 
et al. investigated the relationship between macroH2A1 splice variants, macroH2A1.1 and 
macroH2A1.2, and liver carcinogenesis. It was found that protein levels of both macroH2A1 
isoforms were increased in the livers of very elderly rodents and humans, and were strong 
immunohistochemical markers of human cirrhosis and HCC [112].
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3.3. Chronic hepatitis B
Chronic hepatitis B virus (HBV) infection can lead to the development of chronic hepatitis, 
 cirrhosis, and HCC. HBV infection is associated with age, cell cycle arrest, and CS. In a recent 
study, the authors assessed the HBV antigen production in relation to cell cycle arrest and CS 
in vitro using hepG2 and hepG2.2.15 cell lines [113].The authors found that cell cycle arrest 
induced in vitro by the addition of H
2
O
2 
caused increased levels of supernatant HBsAg and 
HBV DNA and increased expression of HBcAg. In contrast, there was no observed effect on 
HBsAg or HBV DNA production in senescent cells, with only a minor increase in cytoplasmic 
HBcAg staining [113].Widespread telomere shortening is consistent with accelerated aging in 
chronic HBV [114].
3.4. Chronic hepatitis C
Chronic infection with hepatitis C virus (HCV) affects approximately 170 million people 
around the world. Moreover, 20% of these affected people develop cirrhosis and are at great 
risk to develop HCC. An increased risk of HCV-related cirrhosis is associated with hepatic 
steatosis, older age, and higher alcohol consumption [88, 115]. It has been reported that dur-
ing chronic HCV infection, telomere shortening is present in liver tissue [116], likely due 
to increased hepatocyte turnover. Critically short telomeres trigger replicative senescence. 
Marshall et al. found a strong correlation between hepatocyte G1 arrest, dysfunctional hepatic 
regeneration, and increased cirrhosis in patients with chronic HCV. They showed increased 
hepatocyte cell cycle arrest measured by the expression of the mini-chromosome maintenance 
protein 2 (Mcm-2) in liver biopsy samples. The researchers also found that p21 expressed pre-
dominantly in hepatocytes and it was correlated with the stage of fibrosis [107].
3.5. Nonalcohol-related fatty liver disease (NAFLD)
NAFLD is a leading cause of chronic liver disease worldwide [117], which presents a wide 
range of liver disorders including simple steatosis, steatohepatitis, cirrhosis, and HCC [117]. 
In ob/ob mice, NAFLD is associated with an increased expression of the cell cycle inhibi-
tor p21 and impaired liver regeneration [118]. The combination of impaired regeneration 
and increased incidence of cancer in NAFLD suggests accelerated aging. In the literature, 
NAFLD has been separately described by the appearance of premature telomere shortening, 
increased hepatocyte nuclear area, advanced fibrosis, and p21 expression [103, 104]. Recently, 
Aravinthan et al. performed a study on 105 archived formalin-fixed paraffin-embedded liver 
needle biopsy specimens from 70 patients within the spectrum of NAFLD, and 43 liver needle 
biopsies at the time of liver transplantation from age- and sex-matched donor livers served 
as controls. In this study, the authors found a close correlation between hepatic steatosis and 
short telomeres; additionally, the proportion of hepatocytes with DNA damage identified by 
the presence of γ-H2AX increased in parallel with steatosis grade. The authors suggested that 
the accumulation of fat in hepatocytes causes DNA damage and telomere erosion, possibly 
mediated by oxidative stress. A critically short telomere and a break in double-stranded DNA 
lead to CS and permanent cell cycle arrest. The authors also found a pattern of predominant 
hepatocyte G1/S phase cell cycle arrest in NAFLD, with an increased expression of Mcm-2 
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compared to a normal liver. Furthermore, there was increased expression of the p21 protein. 
A striking feature was the association of p21 expression with the fibrosis stage, which sug-
gests an accumulation of senescent hepatocytes with disease progression [105].
3.6. Alcohol-related liver disease
Alcohol-related liver disease (ALD) is one of the leading causes of liver-related morbid-
ity and mortality in the world. ALD encompasses a broad spectrum of liver injury from 
simple steatosis to alcohol-related hepatitis, cirrhosis, and HCC. The pathophysiology of 
ALD is a complex phenomenon; however, oxidative stress is an important factor in the 
disease since alcohol consumption increases the production of ROS and diminishes cel-
lular antioxidant levels [119]. The validity of clinical criteria in predicting outcomes in 
ALD has been studied. In one study, it was shown that the increase of the hepatocyte 
nuclear area was related to hepatic dysfunction and suggests hepatocyte senescence, since 
nuclear enlargement is a recognized morphological characteristic of CS [120]. In contrast, 
irreversible cell arrest that limits the proliferative potential of cell is a hallmark of CS and 
is mediated by p21 [121]. Thus, p21 has a vital role in the stability of cell cycle arrest and 
the induction of senescence [121].
3.7. Senolytic drugs
The accumulation of senescent cells in tissues and organs contributes to age-related dis-
eases; however, the presence of radiations or genotoxic agents may contribute to the devel-
opment of senescence phenotype. This accumulation is important because senescent cells 
contribute to alterations in the microenvironment. This can support conditions for diseases 
such as cancer to develop, but senescent cell quantity is important for organ function in the 
case of aging.
Senolytic agents may be used for clearance of senescent cells in the organs. Chang et al. used 
ABT263, a specific inhibitor of apoptosis genes BCL2 and BCL2L1, to selectively induce apop-
tosis in senescent cells in culture. They carried out experiments using a mouse model with 
known p16-3 MR and administered ABT263 to mice and observed that p16-positive senescent 
cells were depleted in bone marrow, lung, and muscle tissue via apoptosis. The data demon-
strate that ABT263 is a senolytic drug that acts in a highly specific manner on various tissues 
to target senescent cells both in culture and in vivo. These findings significantly advance clini-
cal targeting of cell senescence [122].
4. Conclusion
Until now, the role of CS is poorly understood and little studied in hepatology. There are 
major implications for hepatology in the field of fibrosis and cancer, and liver chronic dis-
eases. Further investigation into the molecular basis of senescence in liver diseases is neces-
sary, and the collaboration between basic and clinical researchers is fundamental to arrive to 
better diagnosis and treatment.
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